XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer
The aim of this study is to elucidate the efficacy and safety of XP and SP for first-line treatment of Advanced Gastric Cancer.
Gastric Cancer
DRUG: SP|DRUG: XP
Progression-free survival rate, at 24weeks from patient enrollment
Time-to treatment failure, 3year|Response rate, 3 year|Overall survival, 3 year|Safety, 3 year
XP and SP are either standard treatment for advanced gastric cancer. The aim of this study is to elucidate the efficacy and safety of Capecitabine/Cisplatin and S-1/Cisplatin for first-line treatment of Advanced Gastric Cancer.